Sandbox ID Skin and Soft Tissues

Jump to navigation Jump to search
  • Animal bite
  • Preferred regimen (1): Amoxicillin-clavulanate 875/125 mg PO bid (Some gram-negative rods are resistant; misses MRSA)
  • Preferred regimen (2): Ampicillin-sulbactam 1.5–3.0 g IV every 6–8 h (Some gram-negative rods are resistant; misses MRSA)
  • Preferred regimen (3): Piperacillin-tazobactam 3.37 g IV every 6–8 h (Misses MRSA)
  • Preferred regimen (4): Doxycycline 100 mg PO bid OR 100 mg IV every 12 h (Excellent activity against Pasteurella multocida; some streptococci are resistant)
  • Preferred regimen (5): Penicillin AND dicloxacillin 500 mg oral
  • Preferred regimen (6): sulfamethoxazole-trimethoprim 160–800 mg PO bid OR IV 5–10 mg/kg/day of TMP component (Good activity against aerobes; poor activity against anaerobes)
  • Preferred regimen (7): Metronidazole250–500 mg PO tid OR 500 mg IV every 8 h (Good activity against anaerobes; no activity against aerobes)
  • Preferred regimen (8): Clindamycin300 mg PO tid OR 600 mg IV every 6–8 h (Good activity against staphylococci, streptococci, and anaerobes; misses P. multocida)
  • Preferred regimen (9): Cefuroxime 500 mg PO bid OR 1 g IV every 12 h
  • Preferred regimen (10): Cefoxitin 1g IV every 6–8 h
  • Preferred regimen (11): Ceftriaxone 1g IV every 12 h
  • Preferred regimen (12): Cefotaxime 1–2 g IV every 6–8 h
  • Preferred regimen (13): Ciprofloxacin 500–750 mg PO bid OR 400 mg IV every 12 h
  • Preferred regimen (14): Levofloxacin 750 mg PO daily OR 750 mg IV daily
  • Preferred regimen (15): Moxifloxacin 400 mg PO daily OR 400 mg IV daily (Monotherapy; good for anaerobes also)
  • Human bite
  • Preferred regimen (15): Amoxicillin-clavulanate 875/125 mg PO bid (Some gram-negative rods are resistant; misses MRSA)
  • Preferred regimen (15): Ampicillin-sulbactam 1.5–3.0 g IV every 6 h (Some gram-negative rods are resistant; misses MRSA)
  • Preferred regimen (15): Doxycycline PO 100 mg bid (Good activity against Eikenella species, staphylococci, and anaerobes; some streptococci are resistant)
  • Preferred regimen (1): (Penicillin Voral 500 mg 4 times daily (qid) for 7–10 days
  • Preferred regimen (2): (Ciprofloxacin 500 mg by mouth (po) bid OR levofloxacin 500 mg intravenously (IV)/po every 24 hours × 60 days is recommended for bioterrorism cases because of presumed aerosol exposure
  • Patients >45 kg: 500 mg on day 1 followed by 250 mg for 4 additional days
  • Patients <45 kg: 10 mg/kg on day 1 and 5 mg/kg for 4 more days
  • Preferred regimen (2): (erythromycin 500 mg by mouth (po) qid OR doxycycline 100 mg bid orally for 2 weeks to 2 months
  • Preferred regimen (1): (streptomycin (15 mg/kg every 12 hours IM) OR gentamicin (1.5 mg/kg every 8 hours IV)
  • Preferred regimen (2): (tetracycline (500 mg qid) OR doxycycline (100 mg bid po) is recommended for treatment of mild cases of tularemia
  • Mastitis
  • Breast Implant
  • Non-puerpural mastitis
  • Postpartum mastitis
  • Abscess
  • Boils
  • Furuncles
  • Furunculosis, recurrent
  • Pilonidal cyst
  • Paronychia
  • Acne
  • Rosacea
  • Acne vulgaris
  • Cutaneous anthrax
  • Bacillary angiomatosis
  • Bullous or vesicular lesions
  • Bullous impetigo
  • Chickenpox
  • Hemorrhagic
  • Herpes simplex
  • Herpes zoster
  • Shingles
  • Staphylococcal scalded skin syndrome
  • Varicella
  • Vibro species
  • Cellulitis
  • Cellulitis in diabetic patients
  • Erysipelas
  • Facial cellulitis
  • Cellulitis in non-diabetic patients
  • Orbital cellulitis
  • Cellulitis caused by Vibro species
  • Burns
  • Non-infected wound
  • Infected wound
  • Erythema nodosum



  • Superficial infections
  • Ecthyma
  • Impetigo
  • Preferred regimen (1): Dicloxacillin 250 mg PO qid
  • Preferred regimen (2): Cephalexin 250 mg PO qid (Pediatric dose : Cephalexin Orally 25–50 mg/kg/d in 3–4 divided doses)
  • Preferred regimen (3): Erythromycin250 mg qid PO (Pediatric dose : Erythromycin 40 mg/kg/d in 3–4 divided doses PO)(Some strains of Staphylococcus aureus and Streptococcus pyogenes may be resistant).
  • Preferred regimen (4): Clindamycin300–400 mg qid PO (Pediatric dose : Clindamycin 20 mg/kg/d in 3 divided doses PO)
  • Preferred regimen (5): Amoxicillin-clavulanate875/125 mg bid po (Pediatric dose : 25 mg/kg/d of the amoxicillin component in 2 divided doses po)
  • Preferred regimen (6): Retapamulin ointment applied to lesions bid (Pediatric dose : Apply to lesions bid)(For patients with limited number of lesions)
  • Preferred regimen (7): Mupirocin ointment applied to lesions bid (Pediatric dose : Apply to lesions bid)(For patients with limited number of lesions)
  • Folliculitis
  • Seborrheic dermatitis
  • Lyme disease
  • Lyme disease, Early
  • Lyme disease, Post-exposure prophylaxis
  • Lyme disease, Post-lyme disease syndrome
  • Ecthyma contagiosum
  • Erythrasma
  • Vascular insufficieny ulcers
  • Wound infections
  • Post-operative, negative Gram-stain
  • Post-operative, positive Gram-stainSurgery of Intestinal or Genitourinary Tract Single-drug regimens Ticarcillin-clavulanate 3.1 g every 6 h IV Piperacillin-tazobactam 3.375 g every 6 h or 4.5 g every 8 h IV Imipenem-cilastatin 500 mg every 6 h IV Meropenem 1 g every 8 h IV Ertapenem 1 g every 24 h IV Combination regimens Ceftriaxone 1 g every 24 h + metronidazole 500 mg every 8 h IV Ciprofloxacin 400 mg IV every 12 h or 750 mg po every 12 h + metronidazole 500 mg every 8 h IV Levofloxacin 750 mg IV every 24 h + metronidazole 500 mg every 8 h IV Ampicillin-sulbactam 3 g every 6 h + gentamicin or tobramycin 5 mg/kg every 24 h IV Surgery of trunk or extremity away from axilla or perineum Oxacillin or nafcillin 2 g every 6 h IV Cefazolin 0.5–1 g every 8 h IV Cephalexin 500 mg every 6 h po SMX-TMP 160–800 mg po every 6 h Vancomycin 15 mg/kg every 12 h IV Surgery of axilla or perineuma Metronidazole 500 mg every 8 h IV plus Ciprofloxacin 400 mg IV every 12 h or 750 mg po every 12 h IV po Levofloxacin 750 mg every 24 h IV po Ceftriaxone 1 g every 24 h
  • Post-trauma
  • Yaws
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_ID_Skin_and_Soft_Tissues&oldid=1102480"